What does the research say about truncating TP53 mutations?

Truncating TP53 mutations

There is 1 paper on truncating TP53 mutations in aging research: none in people yet. The newest story, Nov 9, 2026: “Solid and blood cancers differ in how one gene is altered”.

Biomarker

1 paper studies it1 finding

1 new paper in 30 daysSee all 1 papers on truncating TP53 mutations

“Truncating mutations accounted for 34.2% of solid but 24.4% of hematologic alterations”

One Gene, Two States: Truncating Loss Versus Retained Full-Length p53 in Solid and Hematologic CancersInternational journal of molecular sciences2026doi:10.3390/ijms272110024

In silico1

Associations

Solid tumor

upin humans1

1 study

Solid tumor is associated with truncating TP53 mutations in humans (solid tumors compared with hematologic malignancies) (34.2% versus 24.4%; χ2 = 33.7, p = 2.3 × 10−7).
“Truncating mutations accounted for 34.2% of solid but 24.4% of hematologic alterations”
Humanssolid tumors compared with hematologic malignancies
Solid and blood cancers differ in how one gene is altered
International journal of molecular sciencesNov 9, 2026

Latest

1 paper in 12 months

International Journal of Molecular SciencesNov 9

Solid and blood cancers differ in how one gene is altered

Protein-shortening mutations accounted for 34.2% of samples with the altered gene in solid cancers, versus 24.4% in blood cancers.Protein-shortening mutations accounted for 34.2% of samples with the altered gene in solid cancers, versus 24.4% in blood cancers.

Meta-analysisMechanisms

Paper

Truncating TP53 mutations

Associations

Latest

Solid and blood cancers differ in how one gene is altered

Related